Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECONNECT study of ZYN002 transdermal gel in fragile X syndrome
2021-002542-33Phase 3Active
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Aug 2021
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fragile X syndrome (FXS) comparing Zygel with Placebo (2 arms). Started Aug 2021; status: active.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on 2021-002542-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002542-33.